

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	27.0	85.3	(54.0-127.9)	Male	24	17.1	140.5	(90.0-209.0)
Female	9	9.7	92.5	(42.2-175.6)	Female	16	12.6	126.8	(72.4-206.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	5	4.1	123.4	(39.8-288.1)	Female	5	3.2	157.5	(50.7-367.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	14.9	100.6	(56.3-165.9)
Female	112	94.9	118.1	(97.2-142.1)	Female	9	12.2	73.7	(33.6-139.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.8	132.5	(42.7-309.1)	Male	10	10.4	96.6	(46.3-177.7)
<u>Colon / Rectum</u>					Female	1	4.6	nc	(nc-nc)
Male	29	34.2	84.8	(56.8-121.8)	<u>Ovary</u>				
Female	28	32.8	85.3	(56.6-123.2)	Female	12	9.2	130.5	(67.3-227.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.0	71.2	(22.9-166.2)	Male	9	8.5	106.2	(48.5-201.6)
Female	0	1.9	nc	(nc-nc)	Female	4	8.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.3	nc	(nc-nc)	Male	94	98.9	95.1	(76.8-116.4)
Female	1	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.5	108.2	(43.3-222.9)
Male	26	13.9	186.6	(121.9-273.4)	Female	3	3.7	nc	(nc-nc)
Female	7	7.8	89.7	(36.0-184.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	3.6	167.9	(61.3-365.4)
Male	4	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	6	5.2	116.1	(42.4-252.7)
<u>Leukemia</u>					Female	20	15.0	133.7	(81.6-206.4)
Male	5	9.5	52.9	(17.0-123.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.9	nc	(nc-nc)	Female	25	21.3	117.6	(76.1-173.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	7.1	nc	(nc-nc)	Male	346	356.9	96.9	(87.0-107.7)
Female	2	2.4	nc	(nc-nc)	Female	341	331.5	102.9	(92.2-114.4)
<u>Lung and Bronchus</u>									
Male	51	49.2	103.6	(77.1-136.2)					
Female	52	47.2	110.2	(82.3-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	60.0	86.7	(64.7-113.7)	Male	32	38.6	82.9	(56.7-117.0)
Female	23	23.4	98.1	(62.2-147.3)	Female	28	32.0	87.5	(58.1-126.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.0	58.1	(23.3-119.7)	Male	13	9.5	136.9	(72.8-234.0)
Female	10	10.0	100.3	(48.0-184.4)	Female	5	7.6	65.6	(21.1-153.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	38	33.7	112.9	(79.9-154.9)
Female	228	223.1	102.2	(89.4-116.4)	Female	27	29.7	90.8	(59.8-132.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	9.5	84.3	(36.3-166.2)	Male	31	22.8	136.2	(92.5-193.3)
<u>Colon / Rectum</u>					Female	11	11.2	98.5	(49.1-176.3)
Male	54	75.7	71.4	(53.6-93.1)	<u>Ovary</u>				
Female	85	78.6	108.2	(86.4-133.8)	Female	27	22.1	121.9	(80.3-177.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	15.5	64.3	(30.8-118.3)	Male	22	18.8	117.3	(73.5-177.6)
Female	7	4.6	153.7	(61.6-316.7)	Female	26	20.8	124.8	(81.5-182.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	6.5	nc	(nc-nc)	Male	206	218.6	94.2	(81.8-108.0)
Female	6	4.9	123.0	(44.9-267.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	14.4	104.4	(58.4-172.3)
Male	26	30.8	84.5	(55.2-123.9)	Female	8	8.9	89.9	(38.7-177.2)
Female	15	18.7	80.1	(44.8-132.1)	<u>Testis</u>				
<u>Larynx</u>					Male	12	10.9	109.9	(56.7-192.0)
Male	8	8.9	90.0	(38.7-177.3)	<u>Thyroid</u>				
Female	2	2.6	nc	(nc-nc)	Male	12	12.2	98.7	(50.9-172.4)
<u>Leukemia</u>					Female	32	38.6	82.8	(56.7-117.0)
Male	11	21.3	51.6	(25.7-92.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	16.6	126.6	(78.4-193.6)	Female	41	50.3	81.5	(58.5-110.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	15.6	83.3	(44.3-142.5)	Male	730	798.8	91.4	(84.9-98.3)
Female	6	5.7	105.2	(38.4-229.1)	Female	774	797.9	97.0	(90.3-104.1)
<u>Lung and Bronchus</u>									
Male	115	109.4	105.1	(86.8-126.2)					
Female	96	114.1	84.2	(68.2-102.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.7	85.3	(40.8-156.9)	Male	6	7.3	82.6	(30.2-179.7)
Female	3	4.7	nc	(nc-nc)	Female	6	5.8	102.7	(37.5-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	26	42.4	61.3	(40.0-89.8)	Female	8	5.8	136.9	(58.9-269.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	7	4.4	158.6	(63.5-326.8)
<u>Colon / Rectum</u>					Female	2	2.1	nc	(nc-nc)
Male	16	14.7	108.5	(62.0-176.2)	<u>Ovary</u>				
Female	8	16.0	50.1	(21.6-98.7)	Female	6	4.2	142.1	(51.9-309.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.0	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	31	42.9	72.2	(49.1-102.5)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.8	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.6	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.2	nc	(nc-nc)	Female	9	9.5	94.4	(43.1-179.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	132	153.9	85.8	(71.8-101.7)
Female	1	1.1	nc	(nc-nc)	Female	116	153.8	75.4	(62.3-90.5)
<u>Lung and Bronchus</u>									
Male	20	21.3	93.9	(57.3-145.0)					
Female	21	22.3	94.2	(58.3-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	27.2	128.9	(89.8-179.3)	Male	8	16.6	48.2	(20.7-94.9)
Female	11	10.0	110.3	(55.0-197.4)	Female	6	12.7	47.1	(17.2-102.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.9	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	12	14.4	83.3	(43.0-145.6)
Female	94	95.8	98.2	(79.3-120.1)	Female	8	12.5	64.1	(27.6-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.7	nc	(nc-nc)	Male	12	10.1	118.9	(61.4-207.8)
<u>Colon / Rectum</u>					Female	6	4.7	126.8	(46.3-276.0)
Male	54	33.9	159.2	(119.6-207.7)	<u>Ovary</u>				
Female	37	32.7	113.3	(79.7-156.1)	Female	11	9.4	117.3	(58.5-209.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	7.1	183.1	(97.4-313.2)	Male	12	8.5	141.2	(72.9-246.7)
Female	0	2.0	nc	(nc-nc)	Female	15	8.8	170.0	(95.1-280.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	97	103.1	94.1	(76.3-114.8)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.4	nc	(nc-nc)
Male	19	13.7	139.1	(83.7-217.3)	Female	2	3.7	nc	(nc-nc)
Female	6	8.0	74.6	(27.2-162.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.9	nc	(nc-nc)
Male	8	4.1	195.7	(84.2-385.5)	<u>Thyroid</u>				
Female	3	1.1	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<u>Leukemia</u>					Female	12	14.9	80.4	(41.5-140.4)
Male	16	9.2	174.8	(99.9-283.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.8	nc	(nc-nc)	Female	22	22.2	99.3	(62.2-150.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	7.0	157.3	(78.4-281.5)	Male	415	358.0	115.9	(105.0-127.6)
Female	5	2.4	207.9	(67.0-485.1)	Female	345	337.0	102.4	(91.9-113.8)
<u>Lung and Bronchus</u>									
Male	67	50.3	133.3	(103.3-169.3)					
Female	62	49.7	124.7	(95.6-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.5	90.9	(29.3-212.2)	Male	2	3.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	25	18.9	132.6	(85.8-195.8)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	6	7.0	85.4	(31.2-185.9)	<u>Ovary</u>				
Female	5	6.1	81.7	(26.3-190.7)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	21.3	61.0	(32.4-104.3)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.3	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	153.7	(49.5-358.7)
Male	1	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.3	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	52	74.5	69.8	(52.1-91.5)
Female	0	0.5	nc	(nc-nc)	Female	80	65.1	123.0	(97.5-153.0)
<u>Lung and Bronchus</u>									
Male	10	10.2	98.2	(47.0-180.7)					
Female	16	9.1	175.9	(100.5-285.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.3	152.0	(49.0-354.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	11.5	87.3	(41.8-160.6)
Female	0	0.1	nc	(nc-nc)	Female	7	9.8	71.4	(28.6-147.1)
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	8.3	96.3	(41.5-189.8)
Female	0	0.0	nc	(nc-nc)	Female	5	6.7	74.6	(24.0-174.0)
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	38.0	123.5	(90.8-164.3)	Male	15	23.1	65.1	(36.4-107.3)
Female	16	16.6	96.5	(55.1-156.8)	Female	21	20.7	101.2	(62.6-154.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.9	101.6	(40.7-209.3)	Male	5	5.9	85.4	(27.5-199.2)
Female	8	6.4	125.1	(53.9-246.5)	Female	2	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	11	20.2	54.5	(27.2-97.6)
Female	124	146.1	84.9	(70.6-101.2)	Female	23	20.4	112.7	(71.4-169.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	99.5	(36.3-216.5)	Male	9	13.1	68.7	(31.4-130.4)
<u>Colon / Rectum</u>					Female	9	7.5	120.5	(55.0-228.8)
Male	35	46.7	74.9	(52.2-104.2)	<u>Ovary</u>				
Female	47	55.8	84.3	(61.9-112.0)	Female	16	14.6	109.8	(62.7-178.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	9.4	64.2	(23.4-139.7)	Male	18	11.6	154.5	(91.5-244.2)
Female	5	3.2	154.4	(49.8-360.3)	Female	21	14.8	141.5	(87.6-216.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	3.4	177.6	(64.8-386.5)	Male	116	130.5	88.9	(73.5-106.6)
Female	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.0	89.0	(38.3-175.3)
Male	16	18.2	87.7	(50.1-142.4)	Female	5	6.4	78.1	(25.2-182.3)
Female	15	12.6	119.1	(66.6-196.5)	<u>Testis</u>				
<u>Larynx</u>					Male	6	5.6	106.4	(38.8-231.5)
Male	6	5.3	112.8	(41.2-245.6)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	6.8	73.7	(23.7-171.9)
<u>Leukemia</u>					Female	28	23.8	117.8	(78.2-170.2)
Male	12	12.8	93.8	(48.4-163.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	11.3	71.0	(30.6-139.8)	Female	33	32.3	102.0	(70.2-143.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	9.1	87.5	(37.7-172.3)	Male	427	483.4	88.3	(80.1-97.1)
Female	3	4.0	nc	(nc-nc)	Female	499	536.5	93.0	(85.0-101.5)
<u>Lung and Bronchus</u>									
Male	61	68.4	89.2	(68.2-114.6)					
Female	73	78.9	92.5	(72.5-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.1	99.6	(56.9-161.7)	Male	11	10.1	108.8	(54.2-194.6)
Female	5	5.5	91.6	(29.5-213.8)	Female	11	7.5	147.3	(73.4-263.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	5	2.4	210.3	(67.8-490.7)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	8.8	170.4	(95.3-281.1)
Female	84	58.2	144.3	(115.1-178.6)	Female	11	7.0	157.0	(78.3-280.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	7	6.4	110.0	(44.1-226.6)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	21	20.5	102.5	(63.4-156.7)	<u>Ovary</u>				
Female	18	18.3	98.3	(58.2-155.3)	Female	7	5.5	126.4	(50.6-260.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.3	nc	(nc-nc)	Male	7	5.1	137.4	(55.0-283.0)
Female	0	1.1	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	61	61.9	98.5	(75.4-126.6)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	6	8.4	71.1	(26.0-154.7)	Female	0	2.0	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	16	9.2	173.5	(99.1-281.8)
Male	3	5.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.9	154.0	(56.2-335.2)	Female	12	13.3	90.5	(46.7-158.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.4	nc	(nc-nc)	Male	204	215.7	94.6	(82.0-108.5)
Female	2	1.4	nc	(nc-nc)	Female	224	195.6	114.5	(100.0-130.5)
<u>Lung and Bronchus</u>									
Male	23	29.9	77.0	(48.8-115.5)					
Female	25	27.4	91.2	(59.0-134.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	20.3	113.2	(71.7-169.9)	Male	7	12.4	56.7	(22.7-116.8)
Female	10	8.2	121.6	(58.2-223.7)	Female	2	10.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.7	186.8	(74.8-384.9)	Male	2	3.2	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	10.9	91.8	(44.0-168.9)
Female	74	72.5	102.1	(80.2-128.2)	Female	13	10.1	128.3	(68.2-219.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	2.9	245.3	(98.3-505.5)	Male	6	7.4	81.5	(29.8-177.5)
<u>Colon / Rectum</u>					Female	3	3.7	nc	(nc-nc)
Male	31	25.3	122.7	(83.4-174.2)	<u>Ovary</u>				
Female	34	28.1	120.9	(83.7-169.0)	Female	4	7.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.1	136.2	(54.6-280.7)	Male	10	6.3	158.7	(76.0-291.9)
Female	2	1.6	nc	(nc-nc)	Female	3	7.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.6	nc	(nc-nc)	Male	57	71.5	79.7	(60.4-103.3)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.8	124.7	(45.6-271.5)
Male	11	10.0	109.9	(54.8-196.7)	Female	0	3.2	nc	(nc-nc)
Female	9	6.2	145.5	(66.4-276.3)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.2	89.2	(42.7-164.1)
Male	13	7.0	186.5	(99.2-319.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.7	157.6	(71.9-299.1)	Female	18	16.1	112.0	(66.3-177.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.1	nc	(nc-nc)	Male	265	261.2	101.4	(89.6-114.4)
Female	5	2.0	251.5	(81.0-586.9)	Female	272	265.5	102.4	(90.6-115.4)
<u>Lung and Bronchus</u>									
Male	34	36.5	93.0	(64.4-130.0)					
Female	37	38.6	96.0	(67.6-132.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	29.3	58.0	(33.8-92.9)	Male	28	18.2	153.7	(102.1-222.1)
Female	13	11.2	115.7	(61.5-197.8)	Female	19	15.1	126.0	(75.8-196.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.6	nc	(nc-nc)	Male	6	4.7	128.0	(46.7-278.6)
Female	1	4.9	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	15.9	113.0	(66.9-178.6)
Female	115	110.0	104.6	(86.3-125.5)	Female	18	14.3	125.5	(74.3-198.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.4	nc	(nc-nc)	Male	9	11.3	79.3	(36.2-150.6)
<u>Colon / Rectum</u>					Female	6	5.4	111.3	(40.6-242.3)
Male	24	37.2	64.4	(41.3-95.9)	<u>Ovary</u>				
Female	28	38.1	73.4	(48.8-106.2)	Female	11	10.8	101.5	(50.6-181.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	7.7	nc	(nc-nc)	Male	13	9.2	140.8	(74.9-240.8)
Female	3	2.2	nc	(nc-nc)	Female	6	10.1	59.6	(21.8-129.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	119	109.6	108.6	(90.0-130.0)
Female	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.0	71.5	(23.0-166.8)
Male	13	15.1	86.2	(45.8-147.4)	Female	5	4.3	116.5	(37.5-271.8)
Female	6	9.1	66.2	(24.2-144.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.1	162.5	(52.4-379.3)
Male	1	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	8	5.3	150.8	(64.9-297.2)
<u>Leukemia</u>					Female	26	18.0	144.6	(94.4-211.9)
Male	11	10.2	107.6	(53.6-192.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	8.1	110.6	(50.5-210.0)	Female	25	24.8	101.0	(65.3-149.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	7.9	101.6	(43.8-200.3)	Male	338	388.1	87.1	(78.1-96.9)
Female	4	2.8	nc	(nc-nc)	Female	369	386.8	95.4	(85.9-105.6)
<u>Lung and Bronchus</u>									
Male	16	53.7	29.8	(17.0-48.4)					
Female	32	54.6	58.6	(40.1-82.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	5.0	261.2	(138.9-446.6)	Male	3	2.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	6	2.0	303.6	(110.9-660.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	19	15.3	123.9	(74.6-193.5)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	5	6.1	82.6	(26.6-192.8)	<u>Ovary</u>				
Female	3	5.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	24	16.9	141.8	(90.8-211.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.2	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.2	nc	(nc-nc)	Male	69	61.2	112.7	(87.7-142.7)
Female	1	0.4	nc	(nc-nc)	Female	59	54.1	109.0	(83.0-140.6)
<u>Lung and Bronchus</u>									
Male	5	8.9	56.2	(18.1-131.1)					
Female	7	8.2	85.7	(34.3-176.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	5	3.4	146.9	(47.3-342.8)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.8	133.2	(42.9-310.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	13.0	122.8	(70.1-199.4)
Female	0	0.1	nc	(nc-nc)	Female	10	10.3	97.4	(46.6-179.2)
<u>Lung and Bronchus</u>									
Male	1	1.6	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.1	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	6	1.8	341.2	(124.6-742.7)	Female	8	2.3	342.1	(147.3-674.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	19	16.8	113.2	(68.1-176.8)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	4	6.2	nc	(nc-nc)	<u>Ovary</u>				
Female	9	5.8	154.5	(70.5-293.3)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	20	17.9	111.8	(68.3-172.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.8	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.3	nc	(nc-nc)	Female	6	3.7	160.5	(58.6-349.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.3	nc	(nc-nc)	Male	61	65.1	93.7	(71.7-120.3)
Female	1	0.4	nc	(nc-nc)	Female	78	59.8	130.5	(103.2-162.9)
<u>Lung and Bronchus</u>									
Male	8	9.3	86.4	(37.2-170.2)					
Female	6	8.7	69.1	(25.2-150.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.0	66.9	(24.4-145.7)	Male	4	5.9	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	Female	5	3.8	132.7	(42.8-309.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	5.1	234.6	(121.1-409.8)
Female	37	28.3	130.5	(91.9-179.9)	Female	1	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.1	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.4	nc	(nc-nc)
Male	7	11.4	61.3	(24.5-126.2)	<u>Ovary</u>				
Female	5	10.2	49.2	(15.9-114.9)	Female	1	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	5	2.8	178.0	(57.4-415.4)
Female	0	0.6	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	25	32.0	78.0	(50.5-115.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.2	nc	(nc-nc)
Male	7	4.7	150.4	(60.3-309.9)	Female	1	1.1	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.4	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	10	6.3	159.2	(76.2-292.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.4	nc	(nc-nc)	Male	109	119.3	91.4	(75.0-110.2)
Female	0	0.7	nc	(nc-nc)	Female	103	100.2	102.8	(83.9-124.6)
<u>Lung and Bronchus</u>									
Male	14	16.2	86.2	(47.1-144.6)					
Female	20	14.5	137.8	(84.2-212.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.3	86.3	(37.2-170.1)	Male	6	5.5	108.2	(39.5-235.6)
Female	4	3.6	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	24	32.4	74.0	(47.4-110.1)	Female	3	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	6	11.5	52.2	(19.1-113.6)	<u>Ovary</u>				
Female	12	12.2	98.4	(50.8-171.9)	Female	2	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.4	212.3	(68.4-495.5)	Male	3	2.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	37	33.3	111.1	(78.2-153.2)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.2	nc	(nc-nc)
Male	8	4.5	177.3	(76.4-349.4)	Female	0	1.4	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	6	1.6	386.4	(141.1-841.0)
<u>Leukemia</u>					Female	2	4.7	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.4	nc	(nc-nc)	Female	11	7.4	149.5	(74.5-267.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	118	119.0	99.1	(82.1-118.7)
Female	0	0.9	nc	(nc-nc)	Female	95	117.3	81.0	(65.5-99.0)
<u>Lung and Bronchus</u>									
Male	17	16.8	101.2	(58.9-162.0)					
Female	20	17.4	115.0	(70.2-177.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.3	114.0	(41.6-248.1)	Male	1	3.1	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	21	20.9	100.6	(62.3-153.8)	Female	0	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	5	6.6	75.6	(24.4-176.4)	<u>Ovary</u>				
Female	12	9.5	125.9	(65.0-219.9)	Female	4	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	18	17.7	101.6	(60.2-160.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.7	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	57	65.7	86.8	(65.7-112.5)
Female	0	0.6	nc	(nc-nc)	Female	67	79.7	84.0	(65.1-106.7)
<u>Lung and Bronchus</u>									
Male	10	9.1	110.4	(52.9-203.0)					
Female	11	11.4	96.4	(48.0-172.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.9	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	8	2.1	375.8	(161.8-740.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	14	16.0	87.3	(47.7-146.5)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.7	nc	(nc-nc)
Male	3	5.4	nc	(nc-nc)	<u>Ovary</u>				
Female	8	4.4	182.1	(78.4-358.9)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	16.6	144.3	(92.4-214.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.9	172.6	(55.6-402.9)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.3	nc	(nc-nc)	Male	54	57.5	94.0	(70.6-122.6)
Female	0	0.3	nc	(nc-nc)	Female	58	50.9	113.8	(86.4-147.2)
<u>Lung and Bronchus</u>									
Male	6	7.3	81.7	(29.8-177.8)					
Female	7	6.5	108.0	(43.3-222.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	33.7	86.2	(57.7-123.8)	Male	16	20.7	77.3	(44.2-125.5)
Female	12	12.5	95.8	(49.4-167.4)	Female	12	16.1	74.5	(38.5-130.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.3	111.9	(44.8-230.6)	Male	3	5.3	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	18.1	99.5	(58.9-157.3)
Female	127	117.6	108.0	(90.0-128.5)	Female	17	15.7	108.4	(63.1-173.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.7	128.8	(47.0-280.4)	Male	20	12.4	161.8	(98.8-249.9)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	40	42.1	95.1	(67.9-129.5)	<u>Ovary</u>				
Female	30	42.0	71.4	(48.2-102.0)	Female	10	11.6	86.2	(41.3-158.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.6	151.0	(80.3-258.2)	Male	9	10.5	85.9	(39.2-163.1)
Female	2	2.4	nc	(nc-nc)	Female	9	11.2	80.6	(36.8-153.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	126	122.2	103.1	(85.9-122.8)
Female	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	8.0	150.0	(77.4-262.1)
Male	19	16.8	113.2	(68.1-176.8)	Female	6	4.7	126.6	(46.2-275.6)
Female	11	9.9	111.0	(55.3-198.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	4.3	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	18.7	58.9	(29.3-105.3)
Male	17	11.5	147.3	(85.7-235.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.7	91.6	(39.4-180.4)	Female	27	26.6	101.6	(67.0-147.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.6	58.4	(18.8-136.3)	Male	436	438.8	99.4	(90.3-109.2)
Female	2	3.0	nc	(nc-nc)	Female	397	419.4	94.7	(85.6-104.4)
<u>Lung and Bronchus</u>									
Male	62	61.3	101.2	(77.6-129.7)					
Female	61	61.0	100.0	(76.5-128.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	13	7.2	181.8	(96.7-310.9)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	9	7.8	115.7	(52.8-219.6)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	24	28.3	84.9	(54.4-126.3)
Female	0	0.2	nc	(nc-nc)	Female	26	24.2	107.4	(70.2-157.4)
<u>Lung and Bronchus</u>									
Male	1	4.0	nc	(nc-nc)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.8	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	12	10.9	110.6	(57.1-193.2)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	18	11.1	162.6	(96.3-257.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.9	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	46	39.1	117.6	(86.1-156.9)
Female	0	0.2	nc	(nc-nc)	Female	34	35.0	97.1	(67.2-135.7)
<u>Lung and Bronchus</u>									
Male	1	5.2	nc	(nc-nc)					
Female	3	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	16.8	106.9	(63.3-169.0)	Male	8	11.5	69.6	(30.0-137.1)
Female	8	6.7	119.4	(51.4-235.3)	Female	10	9.6	104.2	(49.9-191.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	10.0	119.5	(61.7-208.7)
Female	66	67.3	98.1	(75.9-124.8)	Female	5	8.6	58.1	(18.7-135.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	3.3	nc	(nc-nc)
Male	21	22.3	94.1	(58.2-143.8)	<u>Ovary</u>				
Female	29	23.7	122.4	(82.0-175.9)	Female	10	6.5	154.5	(73.9-284.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.5	nc	(nc-nc)	Male	7	5.4	130.6	(52.3-269.2)
Female	1	1.3	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.8	nc	(nc-nc)	Male	58	61.7	93.9	(71.3-121.5)
Female	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.2	168.4	(67.5-347.1)
Male	16	9.2	173.4	(99.1-281.7)	Female	1	2.7	nc	(nc-nc)
Female	3	5.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.0	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	7	3.8	185.2	(74.2-381.6)
<u>Leukemia</u>					Female	12	12.0	100.3	(51.8-175.2)
Male	10	6.4	156.1	(74.7-287.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	5.1	nc	(nc-nc)	Female	12	14.3	83.9	(43.3-146.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.7	nc	(nc-nc)	Male	219	230.5	95.0	(82.9-108.5)
Female	3	1.7	nc	(nc-nc)	Female	221	234.8	94.1	(82.1-107.4)
<u>Lung and Bronchus</u>									
Male	21	30.3	69.3	(42.9-105.9)					
Female	30	31.0	96.7	(65.2-138.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	42.4	94.3	(67.4-128.5)	Male	23	26.8	86.0	(54.5-129.0)
Female	11	16.2	67.8	(33.8-121.3)	Female	10	21.7	46.2	(22.1-84.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.3	72.1	(26.3-156.8)	Male	9	6.7	133.6	(61.0-253.7)
Female	6	6.9	86.7	(31.6-188.7)	Female	5	5.3	94.2	(30.4-219.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	18	23.6	76.4	(45.3-120.8)
Female	169	154.8	109.2	(93.3-126.9)	Female	22	20.6	107.0	(67.1-162.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	6.3	204.8	(108.9-350.2)	Male	9	16.2	55.5	(25.3-105.4)
<u>Colon / Rectum</u>					Female	10	7.7	130.4	(62.4-239.8)
Male	52	53.8	96.7	(72.2-126.8)	<u>Ovary</u>				
Female	50	55.1	90.7	(67.3-119.6)	Female	20	15.3	130.9	(79.9-202.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	18	11.0	164.1	(97.2-259.3)	Male	11	13.3	82.9	(41.3-148.3)
Female	3	3.1	nc	(nc-nc)	Female	11	14.5	75.8	(37.8-135.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.9	nc	(nc-nc)	Male	151	153.3	98.5	(83.4-115.5)
Female	5	3.2	157.8	(50.9-368.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	10.2	128.1	(68.1-219.0)
Male	24	21.6	111.0	(71.1-165.2)	Female	6	6.2	96.2	(35.1-209.4)
Female	12	12.9	93.0	(48.0-162.5)	<u>Testis</u>				
<u>Larynx</u>					Male	8	6.1	130.4	(56.2-257.0)
Male	4	6.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
<u>Leukemia</u>					Female	18	25.7	70.0	(41.5-110.7)
Male	7	15.1	46.4	(18.6-95.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	11.6	68.8	(29.6-135.5)	Female	36	34.5	104.4	(73.1-144.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	11.2	53.7	(19.6-116.9)	Male	522	559.4	93.3	(85.5-101.7)
Female	6	4.0	150.8	(55.1-328.2)	Female	543	550.9	98.6	(90.4-107.2)
<u>Lung and Bronchus</u>									
Male	80	76.8	104.2	(82.6-129.7)					
Female	74	78.2	94.6	(74.3-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.2	111.5	(64.9-178.6)	Male	16	11.8	135.3	(77.3-219.7)
Female	3	5.5	nc	(nc-nc)	Female	13	9.7	133.7	(71.1-228.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	10.1	118.7	(61.3-207.4)
Female	79	70.2	112.6	(89.1-140.3)	Female	7	7.7	91.4	(36.6-188.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.4	nc	(nc-nc)	Male	8	7.8	101.9	(43.9-200.8)
<u>Colon / Rectum</u>					Female	0	3.1	nc	(nc-nc)
Male	26	21.5	120.8	(78.9-177.0)	<u>Ovary</u>				
Female	17	19.2	88.5	(51.5-141.7)	Female	9	6.4	139.7	(63.8-265.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.6	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	81	66.2	122.4	(97.2-152.1)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.9	154.5	(56.4-336.2)
Male	8	9.9	81.0	(34.9-159.7)	Female	5	2.1	237.4	(76.5-554.1)
Female	4	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	4.3	140.5	(51.3-305.8)
<u>Leukemia</u>					Female	18	13.7	131.1	(77.7-207.3)
Male	9	6.3	142.8	(65.2-271.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.6	nc	(nc-nc)	Female	17	15.2	111.7	(65.0-178.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.1	97.6	(31.5-227.8)	Male	260	233.1	111.5	(98.4-126.0)
Female	1	1.5	nc	(nc-nc)	Female	225	224.8	100.1	(87.4-114.1)
<u>Lung and Bronchus</u>									
Male	21	29.2	71.9	(44.5-109.9)					
Female	22	27.6	79.6	(49.9-120.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	6.5	168.3	(83.9-301.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	22.4	107.2	(68.7-159.5)
Female	0	0.1	nc	(nc-nc)	Female	11	19.4	56.6	(28.2-101.3)
<u>Lung and Bronchus</u>									
Male	4	2.9	nc	(nc-nc)					
Female	0	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.1	140.9	(67.5-259.2)	Male	4	4.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	8	3.7	215.7	(92.9-425.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	4.3	164.1	(65.7-338.1)
Female	26	27.2	95.6	(62.4-140.1)	Female	4	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.2	nc	(nc-nc)
Male	16	9.6	167.3	(95.6-271.8)	<u>Ovary</u>				
Female	4	8.0	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.3	216.7	(69.8-505.7)
Female	1	0.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	22	28.1	78.4	(49.1-118.7)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.9	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	8	5.9	134.8	(58.0-265.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.2	nc	(nc-nc)	Male	93	100.3	92.8	(74.9-113.6)
Female	0	0.6	nc	(nc-nc)	Female	92	89.2	103.2	(83.2-126.6)
<u>Lung and Bronchus</u>									
Male	9	13.2	68.1	(31.1-129.3)					
Female	14	11.7	119.5	(65.3-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	16.9	59.3	(28.4-109.0)	Male	14	9.9	141.0	(77.0-236.6)
Female	9	5.4	166.3	(75.9-315.8)	Female	6	6.8	87.9	(32.1-191.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	5	8.7	57.2	(18.4-133.4)
Female	59	51.9	113.6	(86.5-146.5)	Female	9	6.8	132.8	(60.6-252.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	2.5	235.8	(86.1-513.3)
Male	10	21.1	47.4	(22.7-87.2)	<u>Ovary</u>				
Female	16	18.6	86.0	(49.1-139.6)	Female	2	5.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	6	4.9	122.9	(44.9-267.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	63	60.3	104.4	(80.2-133.6)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	9	8.2	110.4	(50.4-209.5)	Female	5	2.1	236.8	(76.3-552.6)
Female	2	4.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.2	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	11	7.8	141.2	(70.4-252.6)
Male	1	5.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	9	11.7	77.0	(35.2-146.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.2	nc	(nc-nc)	Male	169	214.9	78.7	(67.2-91.4)
Female	0	1.3	nc	(nc-nc)	Female	187	182.3	102.6	(88.4-118.4)
<u>Lung and Bronchus</u>									
Male	20	30.2	66.2	(40.4-102.3)					
Female	21	25.8	81.6	(50.5-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	18.6	112.6	(69.7-172.2)	Male	6	12.0	50.1	(18.3-109.1)
Female	11	6.3	175.3	(87.4-313.6)	Female	10	8.7	115.1	(55.1-211.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	10.3	87.2	(39.8-165.5)
Female	73	65.6	111.2	(87.2-139.8)	Female	6	8.1	74.3	(27.1-161.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	189.7	(61.1-442.6)	Male	8	7.6	105.6	(45.5-208.0)
<u>Colon / Rectum</u>					Female	4	3.2	nc	(nc-nc)
Male	24	23.9	100.4	(64.3-149.4)	<u>Ovary</u>				
Female	29	20.9	138.7	(92.9-199.2)	Female	8	6.3	126.3	(54.4-248.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.1	117.4	(42.9-255.6)	Male	7	6.0	117.6	(47.1-242.2)
Female	2	1.2	nc	(nc-nc)	Female	9	5.6	162.1	(74.0-307.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	77	73.5	104.8	(82.7-131.0)
Female	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.5	111.8	(36.0-261.0)
Male	8	9.9	80.5	(34.7-158.7)	Female	2	2.3	nc	(nc-nc)
Female	7	5.3	131.9	(52.8-271.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.3	nc	(nc-nc)
Male	7	2.9	237.6	(95.2-489.5)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	5	3.6	139.1	(44.8-324.5)
<u>Leukemia</u>					Female	17	10.7	158.9	(92.5-254.5)
Male	8	6.4	125.3	(54.0-246.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.4	159.5	(63.9-328.7)	Female	26	15.2	170.8	(111.5-250.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.2	nc	(nc-nc)	Male	261	253.8	102.8	(90.7-116.1)
Female	3	1.6	nc	(nc-nc)	Female	277	223.5	124.0	(109.8-139.4)
<u>Lung and Bronchus</u>									
Male	30	34.7	86.4	(58.3-123.4)					
Female	29	31.6	91.9	(61.5-131.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	20.9	86.2	(51.0-136.2)	Male	18	11.9	150.9	(89.4-238.5)
Female	3	7.7	nc	(nc-nc)	Female	19	8.8	215.9	(129.9-337.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.5	173.2	(63.2-376.9)	Male	1	3.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	6	2.5	242.0	(88.4-526.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	10.6	131.9	(72.1-221.4)
Female	71	66.9	106.1	(82.9-133.8)	Female	13	9.3	139.5	(74.2-238.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	5	7.0	71.8	(23.1-167.6)
<u>Colon / Rectum</u>					Female	3	3.4	nc	(nc-nc)
Male	17	25.6	66.5	(38.7-106.5)	<u>Ovary</u>				
Female	27	26.2	103.1	(67.9-150.1)	Female	4	6.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.0	nc	(nc-nc)	Male	6	6.4	94.3	(34.4-205.3)
Female	2	1.5	nc	(nc-nc)	Female	9	6.9	130.0	(59.3-246.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	65	69.7	93.2	(71.9-118.8)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.9	nc	(nc-nc)
Male	7	9.6	72.8	(29.1-149.9)	Female	3	3.0	nc	(nc-nc)
Female	2	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.1	225.1	(90.2-463.8)
<u>Leukemia</u>					Female	8	9.4	84.8	(36.5-167.1)
Male	6	6.9	86.5	(31.6-188.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.2	nc	(nc-nc)	Female	9	14.8	60.9	(27.8-115.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.9	nc	(nc-nc)	Male	235	257.0	91.4	(80.1-103.9)
Female	2	1.8	nc	(nc-nc)	Female	259	243.6	106.3	(93.8-120.1)
<u>Lung and Bronchus</u>									
Male	25	36.7	68.0	(44.0-100.4)					
Female	43	35.8	120.2	(87.0-162.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	61.0	98.4	(75.1-126.7)	Male	34	38.4	88.5	(61.3-123.7)
Female	25	25.0	100.2	(64.8-147.9)	Female	41	32.3	126.9	(91.1-172.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	11.8	127.5	(71.3-210.3)	Male	6	9.7	61.7	(22.5-134.3)
Female	13	10.2	127.2	(67.7-217.5)	Female	7	8.2	85.7	(34.3-176.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	40	33.3	120.0	(85.7-163.4)
Female	230	239.1	96.2	(84.1-109.4)	Female	26	31.3	83.1	(54.3-121.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	14	9.6	146.4	(80.0-245.7)	Male	32	23.3	137.3	(93.9-193.8)
<u>Colon / Rectum</u>					Female	11	11.8	93.5	(46.6-167.4)
Male	76	76.9	98.8	(77.9-123.7)	<u>Ovary</u>				
Female	88	83.2	105.8	(84.9-130.4)	Female	27	23.4	115.6	(76.2-168.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	16.1	180.5	(120.9-259.2)	Male	21	19.2	109.6	(67.8-167.5)
Female	2	4.9	nc	(nc-nc)	Female	22	22.2	99.2	(62.2-150.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	5.1	157.2	(67.7-309.9)	Male	215	229.3	93.7	(81.6-107.2)
Female	4	4.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	14.5	48.1	(19.3-99.2)
Male	44	31.4	140.0	(101.7-188.0)	Female	11	9.4	117.3	(58.5-209.9)
Female	30	20.0	149.7	(101.0-213.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	8.0	87.9	(35.2-181.0)
Male	6	9.2	65.1	(23.8-141.8)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	12	11.5	104.2	(53.8-182.0)
<u>Leukemia</u>					Female	39	38.2	102.2	(72.7-139.7)
Male	20	21.1	94.6	(57.8-146.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	17.3	69.3	(35.7-121.0)	Female	44	54.0	81.5	(59.2-109.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	16.1	86.8	(47.4-145.7)	Male	833	812.0	102.6	(95.7-109.8)
Female	3	6.1	nc	(nc-nc)	Female	860	843.6	101.9	(95.2-109.0)
<u>Lung and Bronchus</u>									
Male	121	112.7	107.3	(89.1-128.2)					
Female	154	122.5	125.7	(106.6-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	6.5	122.9	(52.9-242.2)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	5	2.0	249.4	(80.4-582.0)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	7.3	110.0	(47.4-216.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	26.4	72.0	(43.3-112.5)
Female	0	0.1	nc	(nc-nc)	Female	21	21.6	97.2	(60.2-148.7)
<u>Lung and Bronchus</u>									
Male	4	3.5	nc	(nc-nc)					
Female	0	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.0	74.7	(34.1-141.8)	Male	11	8.4	130.4	(65.0-233.4)
Female	2	4.5	nc	(nc-nc)	Female	10	7.1	141.6	(67.8-260.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
Female	48	49.9	96.2	(70.9-127.5)	Female	8	6.0	133.3	(57.4-262.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	7	5.3	131.1	(52.5-270.2)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	14	16.0	87.4	(47.8-146.7)	<u>Ovary</u>				
Female	20	15.1	132.1	(80.6-204.0)	Female	4	4.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.4	146.7	(47.3-342.3)	Male	5	3.9	127.7	(41.1-298.0)
Female	3	0.9	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.4	nc	(nc-nc)	Male	33	48.9	67.5	(46.4-94.8)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	11	6.9	159.2	(79.4-284.9)	Female	2	1.7	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.3	96.7	(44.1-183.6)
Male	4	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	11	11.2	98.3	(49.0-175.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.6	nc	(nc-nc)	Male	160	172.4	92.8	(79.0-108.4)
Female	2	1.1	nc	(nc-nc)	Female	173	168.4	102.7	(88.0-119.2)
<u>Lung and Bronchus</u>									
Male	27	22.6	119.4	(78.7-173.7)					
Female	26	22.7	114.5	(74.8-167.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	18.7	101.5	(61.1-158.5)	Male	21	11.4	183.5	(113.6-280.6)
Female	11	6.8	160.9	(80.2-288.0)	Female	12	8.5	140.6	(72.6-245.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	10.0	170.0	(99.0-272.2)
Female	73	65.4	111.6	(87.5-140.3)	Female	15	8.5	176.2	(98.5-290.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.2	nc	(nc-nc)
Male	17	23.6	72.1	(42.0-115.4)	<u>Ovary</u>				
Female	31	23.2	133.8	(90.9-190.0)	Female	10	6.4	156.9	(75.1-288.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	8	5.9	136.0	(58.6-268.0)
Female	1	1.3	nc	(nc-nc)	Female	10	6.1	163.0	(78.0-299.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	85	69.8	121.8	(97.3-150.6)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.4	nc	(nc-nc)
Male	8	9.5	84.2	(36.3-166.0)	Female	3	2.6	nc	(nc-nc)
Female	7	5.4	129.9	(52.1-267.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	13	9.8	132.9	(70.7-227.2)
Male	8	6.3	126.6	(54.5-249.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.7	nc	(nc-nc)	Female	14	14.8	94.8	(51.8-159.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.9	nc	(nc-nc)	Male	234	245.6	95.3	(83.5-108.3)
Female	4	1.7	nc	(nc-nc)	Female	255	229.4	111.2	(97.9-125.7)
<u>Lung and Bronchus</u>									
Male	12	34.4	34.9	(18.0-61.0)					
Female	20	33.0	60.6	(37.0-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.2	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	12	10.7	112.4	(58.0-196.4)	Female	3	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Ovary</u>				
Female	5	3.2	156.6	(50.5-365.6)	Female	2	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.6	94.9	(47.3-169.8)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	4	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	34	41.5	81.9	(56.7-114.4)
Female	0	0.2	nc	(nc-nc)	Female	49	35.2	139.1	(102.9-183.9)
<u>Lung and Bronchus</u>									
Male	4	5.7	nc	(nc-nc)					
Female	6	4.8	125.7	(45.9-273.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.9	64.0	(25.6-131.8)	Male	11	6.1	180.8	(90.1-323.6)
Female	1	4.8	nc	(nc-nc)	Female	7	5.2	135.8	(54.4-279.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	8	5.5	145.8	(62.8-287.2)
Female	27	36.9	73.1	(48.2-106.4)	Female	7	5.7	123.2	(49.3-253.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.0	nc	(nc-nc)
Male	9	13.1	68.8	(31.4-130.7)	<u>Ovary</u>				
Female	15	16.5	90.9	(50.8-149.9)	Female	2	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.6	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	68	35.6	191.2	(148.5-242.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.0	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	8	8.2	97.7	(42.0-192.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.4	nc	(nc-nc)	Male	156	132.6	117.6	(99.9-137.6)
Female	0	1.1	nc	(nc-nc)	Female	119	142.8	83.3	(69.0-99.7)
<u>Lung and Bronchus</u>									
Male	20	19.1	104.6	(63.8-161.5)					
Female	30	21.3	140.6	(94.9-200.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	19.5	112.7	(70.6-170.6)	Male	16	13.5	118.9	(67.9-193.1)
Female	10	7.4	136.0	(65.1-250.2)	Female	12	10.8	111.0	(57.3-193.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.4	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	11.6	86.3	(41.3-158.7)
Female	101	78.4	128.8	(104.9-156.5)	Female	8	9.6	83.5	(35.9-164.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.5	nc	(nc-nc)	Male	7	8.5	82.5	(33.1-170.0)
<u>Colon / Rectum</u>					Female	6	3.7	161.1	(58.8-350.6)
Male	35	25.7	136.2	(94.8-189.4)	<u>Ovary</u>				
Female	21	24.8	84.6	(52.3-129.3)	Female	9	7.5	119.9	(54.7-227.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.5	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	12	6.5	184.3	(95.1-321.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.0	nc	(nc-nc)	Male	87	78.7	110.6	(88.6-136.4)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.8	nc	(nc-nc)
Male	14	11.1	126.3	(69.0-212.0)	Female	3	2.8	nc	(nc-nc)
Female	8	6.3	127.1	(54.7-250.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.4	113.0	(36.4-263.8)
<u>Leukemia</u>					Female	11	14.0	78.8	(39.3-141.1)
Male	11	7.3	150.2	(74.9-268.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	5.6	161.8	(73.8-307.1)	Female	23	17.6	131.0	(83.0-196.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.7	nc	(nc-nc)	Male	307	276.4	111.1	(99.0-124.2)
Female	7	1.8	380.0	(152.2-783.0)	Female	318	267.3	119.0	(106.3-132.8)
<u>Lung and Bronchus</u>									
Male	46	36.7	125.2	(91.6-167.0)					
Female	49	36.5	134.3	(99.3-177.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.7	115.1	(55.1-211.7)	Male	3	6.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	5	1.4	346.6	(111.7-808.8)
Female	0	1.6	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	95.9	(30.9-223.9)
Female	29	33.6	86.3	(57.8-123.9)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	15	11.5	130.8	(73.2-215.8)	<u>Ovary</u>				
Female	6	10.6	56.4	(20.6-122.7)	Female	5	3.2	154.8	(49.9-361.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.4	206.8	(66.6-482.6)	Male	3	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	36	34.6	104.2	(72.9-144.2)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	5	2.7	184.7	(59.5-431.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	6.2	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.4	nc	(nc-nc)	Female	10	7.5	134.1	(64.2-246.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.5	nc	(nc-nc)	Male	132	122.7	107.6	(90.0-127.6)
Female	0	0.8	nc	(nc-nc)	Female	105	115.2	91.2	(74.6-110.4)
<u>Lung and Bronchus</u>									
Male	21	16.2	129.9	(80.4-198.6)					
Female	18	15.6	115.3	(68.3-182.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.8	115.1	(78.7-162.5)	Male	25	16.8	148.7	(96.2-219.5)
Female	4	11.1	nc	(nc-nc)	Female	14	13.4	104.4	(57.0-175.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.0	179.8	(82.0-341.3)	Male	2	4.4	nc	(nc-nc)
Female	6	4.3	140.3	(51.2-305.4)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	16	14.7	108.6	(62.0-176.3)
Female	96	101.2	94.8	(76.8-115.8)	Female	13	13.7	95.1	(50.6-162.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	10	10.2	98.0	(46.9-180.3)
<u>Colon / Rectum</u>					Female	10	5.0	198.7	(95.1-365.4)
Male	25	34.8	71.8	(46.5-106.0)	<u>Ovary</u>				
Female	29	38.2	75.9	(50.8-109.1)	Female	9	10.0	90.3	(41.2-171.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	7.1	70.2	(22.6-163.8)	Male	4	8.7	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	5	10.0	49.9	(16.1-116.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	95	100.8	94.2	(76.2-115.2)
Female	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.6	nc	(nc-nc)
Male	18	13.8	130.6	(77.3-206.4)	Female	2	4.4	nc	(nc-nc)
Female	5	8.4	59.2	(19.1-138.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.7	185.5	(59.8-433.0)
Male	6	4.1	147.1	(53.7-320.1)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.7	105.6	(34.0-246.4)
<u>Leukemia</u>					Female	23	14.9	154.0	(97.6-231.1)
Male	8	9.4	84.9	(36.5-167.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.7	104.2	(44.9-205.4)	Female	23	22.5	102.0	(64.7-153.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.1	98.6	(39.5-203.2)	Male	338	359.6	94.0	(84.2-104.6)
Female	2	2.7	nc	(nc-nc)	Female	318	362.7	87.7	(78.3-97.9)
<u>Lung and Bronchus</u>									
Male	39	50.4	77.3	(55.0-105.7)					
Female	35	52.0	67.3	(46.9-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.7	136.2	(43.9-317.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	12.8	86.0	(42.9-153.9)
Female	0	0.1	nc	(nc-nc)	Female	8	10.9	73.4	(31.6-144.7)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	20.1	99.4	(60.7-153.5)	Male	19	12.5	151.6	(91.2-236.8)
Female	11	8.1	135.2	(67.4-242.0)	Female	16	10.5	152.6	(87.1-247.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.8	159.1	(58.1-346.4)	Male	0	3.2	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	10.9	155.3	(90.4-248.6)
Female	86	75.1	114.5	(91.6-141.4)	Female	18	10.1	177.6	(105.2-280.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.2	nc	(nc-nc)	Male	7	7.4	94.2	(37.7-194.0)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	21	25.3	82.9	(51.3-126.8)	<u>Ovary</u>				
Female	23	27.6	83.4	(52.9-125.2)	Female	12	7.4	162.8	(84.0-284.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	5.1	195.1	(93.4-358.8)	Male	4	6.3	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	9	7.3	123.5	(56.4-234.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	62	71.6	86.6	(66.4-111.0)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	4.8	nc	(nc-nc)
Male	19	10.1	188.4	(113.4-294.2)	Female	1	3.2	nc	(nc-nc)
Female	10	6.3	157.7	(75.5-290.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.7	182.7	(58.9-426.2)
Male	3	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	3.7	134.0	(43.2-312.6)
<u>Leukemia</u>					Female	9	12.4	72.6	(33.1-137.9)
Male	10	6.9	144.7	(69.3-266.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.7	nc	(nc-nc)	Female	28	16.5	169.9	(112.8-245.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.1	97.4	(31.4-227.4)	Male	281	261.6	107.4	(95.2-120.7)
Female	0	2.0	nc	(nc-nc)	Female	311	270.1	115.1	(102.7-128.7)
<u>Lung and Bronchus</u>									
Male	38	36.3	104.7	(74.1-143.8)					
Female	49	38.8	126.2	(93.4-166.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	42.8	100.6	(72.8-135.5)	Male	31	27.0	115.0	(78.1-163.2)
Female	14	16.3	85.9	(46.9-144.2)	Female	17	21.3	79.9	(46.5-128.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.3	84.7	(33.9-174.6)	Male	7	6.8	103.3	(41.4-212.8)
Female	3	6.7	nc	(nc-nc)	Female	6	5.3	113.8	(41.5-247.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	20	23.4	85.6	(52.3-132.2)
Female	179	155.9	114.8	(98.6-132.9)	Female	25	20.4	122.6	(79.3-181.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.3	nc	(nc-nc)	Male	19	16.0	118.7	(71.4-185.3)
<u>Colon / Rectum</u>					Female	10	7.7	129.7	(62.1-238.4)
Male	59	53.6	110.1	(83.8-142.0)	<u>Ovary</u>				
Female	63	53.5	117.8	(90.5-150.7)	Female	9	15.2	59.0	(26.9-112.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	11.2	107.4	(55.4-187.6)	Male	16	13.4	119.7	(68.4-194.3)
Female	2	3.2	nc	(nc-nc)	Female	13	14.4	90.2	(48.0-154.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.8	nc	(nc-nc)	Male	142	159.9	88.8	(74.8-104.7)
Female	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	10.2	88.3	(40.3-167.7)
Male	21	21.9	95.8	(59.3-146.5)	Female	3	6.1	nc	(nc-nc)
Female	11	13.1	83.7	(41.7-149.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.1	nc	(nc-nc)
Male	7	6.4	109.3	(43.8-225.3)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
<u>Leukemia</u>					Female	32	25.4	125.8	(86.0-177.6)
Male	19	14.7	129.2	(77.7-201.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	11.3	132.5	(74.1-218.5)	Female	33	35.4	93.1	(64.1-130.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	11.1	nc	(nc-nc)	Male	575	568.1	101.2	(93.1-109.8)
Female	3	3.9	nc	(nc-nc)	Female	601	551.4	109.0	(100.5-118.1)
<u>Lung and Bronchus</u>									
Male	100	79.2	126.2	(102.7-153.5)					
Female	99	81.0	122.3	(99.4-148.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	158	172.0	91.9	(78.1-107.3)	Male	57	108.0	52.8	(40.0-68.4)
Female	71	70.0	101.4	(79.2-127.9)	Female	48	93.8	51.2	(37.7-67.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	29	34.4	84.3	(56.5-121.1)	Male	34	26.9	126.2	(87.4-176.4)
Female	35	30.2	116.0	(80.8-161.3)	Female	15	22.7	66.2	(37.0-109.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	4.7	105.4	(34.0-246.1)	Male	92	95.3	96.5	(77.8-118.3)
Female	572	643.0	89.0	(81.8-96.6)	Female	97	88.3	109.8	(89.0-134.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	37	27.6	134.2	(94.5-185.0)	Male	52	62.9	82.7	(61.8-108.5)
<u>Colon / Rectum</u>					Female	29	32.6	89.0	(59.6-127.8)
Male	220	215.6	102.1	(89.0-116.5)	<u>Ovary</u>				
Female	215	238.8	90.0	(78.4-102.9)	Female	57	64.2	88.8	(67.3-115.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	54	43.1	125.3	(94.1-163.5)	Male	51	53.2	95.8	(71.3-126.0)
Female	15	13.6	110.6	(61.9-182.4)	Female	44	62.9	70.0	(50.8-94.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	17	17.6	96.5	(56.2-154.5)	Male	504	600.5	83.9	(76.8-91.6)
Female	7	14.5	48.4	(19.4-99.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	46	41.1	111.9	(81.9-149.3)
Male	78	85.6	91.2	(72.1-113.8)	Female	32	27.4	117.0	(80.0-165.1)
Female	52	54.3	95.8	(71.5-125.6)	<u>Testis</u>				
<u>Larynx</u>					Male	26	28.7	90.7	(59.2-132.9)
Male	31	24.6	126.0	(85.6-178.8)	<u>Thyroid</u>				
Female	7	7.3	95.9	(38.4-197.6)	Male	35	33.0	105.9	(73.8-147.3)
<u>Leukemia</u>					Female	98	111.1	88.2	(71.6-107.5)
Male	42	62.2	67.5	(48.6-91.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	49	51.0	96.1	(71.1-127.1)	Female	170	141.6	120.1	(102.7-139.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	64	43.2	148.2	(114.1-189.2)	Male	2110	2239.9	94.2	(90.2-98.3)
Female	30	17.1	175.8	(118.6-250.9)	Female	2231	2340.1	95.3	(91.4-99.4)
<u>Lung and Bronchus</u>									
Male	356	308.2	115.5	(103.8-128.2)					
Female	358	331.6	108.0	(97.1-119.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	9	5.5	164.0	(74.9-311.4)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	6.3	127.1	(54.7-250.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	21.6	78.6	(45.8-125.9)
Female	0	0.1	nc	(nc-nc)	Female	20	17.9	111.6	(68.2-172.4)
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	4	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.5	133.7	(73.1-224.4)	Male	9	7.2	125.2	(57.1-237.6)
Female	9	4.3	211.2	(96.4-400.9)	Female	11	5.9	186.5	(93.0-333.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	41	43.1	95.1	(68.2-129.0)	Female	1	5.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.1	nc	(nc-nc)
Male	18	14.1	127.9	(75.7-202.1)	<u>Ovary</u>				
Female	22	15.1	146.2	(91.6-221.3)	Female	5	4.1	121.5	(39.1-283.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	49	39.8	123.1	(91.1-162.8)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	3	5.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.3	82.7	(30.2-180.0)
Male	3	4.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	3.2	220.7	(88.4-454.8)	Female	9	9.1	98.7	(45.0-187.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	149	145.2	102.6	(86.8-120.5)
Female	3	1.1	nc	(nc-nc)	Female	162	148.9	108.8	(92.7-126.9)
<u>Lung and Bronchus</u>									
Male	16	19.0	84.2	(48.1-136.7)					
Female	14	19.9	70.3	(38.4-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	54.2	132.8	(103.9-167.3)	Male	49	27.8	176.3	(130.4-233.1)
Female	26	19.9	130.4	(85.1-191.0)	Female	37	19.8	187.0	(131.6-257.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.4	81.0	(29.6-176.4)	Male	10	7.8	127.8	(61.2-235.1)
Female	8	6.4	125.8	(54.2-247.9)	Female	8	6.3	126.2	(54.3-248.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	33	25.1	131.6	(90.6-184.8)
Female	166	150.9	110.0	(93.9-128.1)	Female	19	23.2	81.8	(49.2-127.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.9	121.7	(44.4-264.8)	Male	14	15.0	93.5	(51.1-156.8)
<u>Colon / Rectum</u>					Female	11	8.1	136.2	(67.9-243.8)
Male	62	62.7	98.9	(75.8-126.7)	<u>Ovary</u>				
Female	48	66.4	72.3	(53.3-95.8)	Female	14	15.5	90.3	(49.3-151.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	12.0	99.9	(51.6-174.6)	Male	17	16.0	106.5	(62.0-170.5)
Female	8	3.9	204.5	(88.1-403.0)	Female	22	18.0	122.3	(76.6-185.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.5	237.4	(86.7-516.7)	Male	211	164.9	128.0	(111.3-146.5)
Female	2	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	12.3	56.7	(22.7-116.8)
Male	19	22.0	86.3	(52.0-134.8)	Female	8	7.7	103.4	(44.5-203.7)
Female	14	13.8	101.1	(55.2-169.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.0	nc	(nc-nc)
Male	7	6.8	103.4	(41.4-213.1)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	8	6.2	129.1	(55.6-254.4)
<u>Leukemia</u>					Female	14	18.4	76.0	(41.5-127.5)
Male	17	16.4	103.5	(60.2-165.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	12.5	143.6	(85.1-227.0)	Female	28	34.0	82.4	(54.8-119.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	11.0	90.9	(43.5-167.1)	Male	708	620.1	114.2	(105.9-122.9)
Female	3	4.6	nc	(nc-nc)	Female	623	583.6	106.7	(98.5-115.5)
<u>Lung and Bronchus</u>									
Male	95	93.8	101.2	(81.9-123.8)					
Female	99	92.8	106.7	(86.7-129.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;